← Eichor
Study identifier: NCT07235319 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC

Condition: Nasopharangeal Cancer · Distant Metastasis  ·  Sponsor: Sun Yat-sen University

PhasePhase 3
Planned participants260
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This phase III randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus salvage locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma. The study aims to evaluate whether salvage locoregional radiotherapy is non-inferior to immediate radiotherapy following PD-1 inhibitor plus GP in de novo metastatic NPC, with potential for reduced toxicity.

This description comes directly from the study's public registry record.

Talk to the study team

Haiqiang Mai, PhD, MD  ·  +86-020-87343643  ·  maihq@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (5)

Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting
Hunan Cancer HospitalChangsha, ChinaNot Yet Recruiting
Fujian Cancer HospitalFuzhou, ChinaNot Yet Recruiting
Zhejiang Cancer HospitalHangzhou, ChinaNot Yet Recruiting
Guangxi Medical University Cancer HospitalNanning, ChinaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07235319